Kymera Therapeutics (KYMR) Competitors $40.62 -0.23 (-0.56%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$40.62 +0.01 (+0.01%) As of 08/8/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KYMR vs. QGEN, MRNA, ASND, VTRS, BBIO, VRNA, BPMC, ROIV, GRFS, and LEGNShould you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Kymera Therapeutics vs. Its Competitors Qiagen Moderna Ascendis Pharma A/S Viatris BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Roivant Sciences Grifols Legend Biotech QIAGEN (NYSE:QGEN) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership. Does the media prefer QGEN or KYMR? In the previous week, QIAGEN had 20 more articles in the media than Kymera Therapeutics. MarketBeat recorded 22 mentions for QIAGEN and 2 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.97 beat QIAGEN's score of 0.76 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QIAGEN 7 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, QGEN or KYMR? QIAGEN has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Is QGEN or KYMR more profitable? QIAGEN has a net margin of 18.30% compared to Kymera Therapeutics' net margin of -409.07%. QIAGEN's return on equity of 14.77% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets QIAGEN18.30% 14.77% 8.86% Kymera Therapeutics -409.07%-30.11%-25.65% Which has better valuation and earnings, QGEN or KYMR? QIAGEN has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQIAGEN$1.98B5.40$83.59M$1.6928.41Kymera Therapeutics$47.07M56.20-$223.86M-$3.10-13.10 Do insiders and institutionals have more ownership in QGEN or KYMR? 70.0% of QIAGEN shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer QGEN or KYMR? QIAGEN currently has a consensus target price of $49.69, indicating a potential upside of 3.47%. Kymera Therapeutics has a consensus target price of $59.11, indicating a potential upside of 45.52%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than QIAGEN.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score QIAGEN 0 Sell rating(s) 8 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.27Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 16 Buy rating(s) 3 Strong Buy rating(s) 3.10 SummaryQIAGEN beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks. Get Kymera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KYMR vs. The Competition Export to ExcelMetricKymera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.65B$2.99B$5.51B$9.72BDividend YieldN/A2.45%4.60%4.12%P/E Ratio-13.1017.2130.0124.75Price / Sales56.20312.02450.7297.72Price / CashN/A41.7736.7758.47Price / Book3.157.318.185.59Net Income-$223.86M-$54.43M$3.26B$265.99M7 Day Performance-5.45%0.01%6.13%5.07%1 Month Performance-10.15%0.63%0.07%0.61%1 Year Performance-1.98%8.41%36.31%22.83% Kymera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KYMRKymera Therapeutics3.3468 of 5 stars$40.62-0.6%$59.11+45.5%-2.0%$2.65B$47.07M-13.10170Positive NewsQGENQiagen3.5567 of 5 stars$50.27+0.7%$49.40-1.7%+8.7%$11.10B$1.98B126.045,765News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionMRNAModerna4.3316 of 5 stars$27.64+0.1%$45.61+65.0%-69.2%$10.68B$3.24B-3.675,800Earnings ReportAnalyst RevisionASNDAscendis Pharma A/S3.424 of 5 stars$184.15+5.5%$223.67+21.5%+50.8%$10.67B$393.54M-29.321,017Trending NewsEarnings ReportAnalyst ForecastGap UpVTRSViatris1.7928 of 5 stars$8.94+1.5%$10.40+16.3%-17.7%$10.34B$14.74B-2.8232,000Trending NewsEarnings ReportDividend AnnouncementAnalyst UpgradeShort Interest ↑BBIOBridgeBio Pharma4.7302 of 5 stars$47.75+0.8%$61.18+28.1%+90.7%$8.99B$221.90M-13.53400Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share1.5639 of 5 stars$105.47+0.3%$109.00+3.3%+365.4%$8.95B$42.28M-52.7430Positive NewsEarnings ReportInsider TradeBPMCBlueprint Medicines0.6453 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences2.157 of 5 stars$11.51+1.8%$16.50+43.4%+3.3%$7.69B$29.05M-46.04860Positive NewsUpcoming EarningsGRFSGrifols3.3343 of 5 stars$10.72-0.6%$10.30-3.9%+47.9%$7.41B$7.81B9.1623,822Positive NewsAnalyst ForecastLEGNLegend Biotech3.8262 of 5 stars$38.45-0.9%$73.33+90.7%-33.8%$7.13B$627.24M-65.172,609News CoverageUpcoming EarningsAnalyst Revision Related Companies and Tools Related Companies QGEN Competitors MRNA Competitors ASND Competitors VTRS Competitors BBIO Competitors VRNA Competitors BPMC Competitors ROIV Competitors GRFS Competitors LEGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KYMR) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KYMR Stock Alerts